章里西,吴炜,张抒扬

• 1:中国医学科学院北京协和医学院
• 2:中国医学科学院北京协和医学院北京协和医院心内科

摘要(Abstract)：

<正>心房颤动(atrial fibrillation,AF)是最常见的心律失常之一,与卒中等栓塞事件的发生直接相关。目前我国30~85岁人群AF的总患病率为0.77%~[1],AF中卒中的相对发生率为17.5%~[2]。《2012年欧洲心脏病学会(ESC)心房颤动管理指南》~[3]、《2014年美国心脏协会(AHA)/美国心脏病学会(ACC)/美国心律学会(HRS)心房颤动患者管理指

关键词(KeyWords)： 心房颤动;经皮冠状动脉介入治疗;抗凝;抗血小板

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 章里西,吴炜,张抒扬

参考文献(References)：

• [1]周自强,胡大一,陈捷,等.中国心房颤动现状的流行病学研究.中华内科杂志,2004,43(7):491-494.
• [2]李峥,刘旭.抗凝药物在心房颤动治疗中的新进展,中国介入心脏病学杂志,2011,19(1):50-52.
• [3]Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.Europace,2012,14(10):1385-1413.
• [4]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol,2014,64(21):2305-2307.
• [5]中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会,中国生物医学工程学心律分会,等.心房颤动抗凝治疗中国专家共识.中华内科杂志,2012,51(11):916-921.
• [6]Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS),European Association for Percutaneous Cardiovascular Interventions(EAPCI),Wijns W,,et al.Guidelines on myocardial revascularization.Eur Heart J,2010,31(20):2501-2555.
• [7]Rubboli A,Colletta M,Valencia J,et al.Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting.J Interv Cardiol,2009,22(4):390-397.
• [8]Connolly S,Pogue J,Hart R,et al.Clopidogrel plus aspirin versus?oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVE W):a randomised controlled trial.Lancet,2006,367(9526):1903-1912.
• [9]Leon MB,Baim DS,Popma JJ,et al.A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.Stent Anticoagulation Restenosis Study Investigators.N Engl J Med,1998,339(23):1665-1671.
• [10]Bavishi C,Koulova A,Bangalore S,et al.Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation:A meta-analysis of observational studies.Catheter Cardiovasc Interv,2016,88(1):E12-22.
• [11]Lip GY,Windecker S,Huber K,et al.Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions:a joint consensus document of the European Society of Cardiology Working Group on Thrombosis,European Heart Rhythm Association(EHRA),European Association of Percutaneous Cardiovascular Interventions(EAPCI)and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS)and Asia-Pacific Heart Rhythm Society(APHRS).Eur Heart J,2014,35(45):3155-3179.
• [12]Fiedler KA,Maeng M,Mehilli J,et al.Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DrugEluting Stent Implantation:The ISAR-TRIPLE Trial.J Am Coll Cardiol,2015,65(16):1619-1629.
• [13]Dewilde WJ,Oirbans T,Verheugt FW,et al.Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:an open-label,randomised,controlled trial.Lancet,2013,381(9872):1107-1115.
• [14]Anticoagulation in Stent Intervention(MUSICA-2).Clinical Trials.gov.
• [15]Gibson CM,Mehran R,Bode C,et al.An open-label,randomized,controlled,multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention(PIONEER AFPCI).Am Heart J,2015,169(4):472-478.e5.
• [16]Evaluation of Dual Therapy With Dabigatran vs.Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting(REDUAL-PCI).Clinical Trials.gov.
• [17]Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention.Clinical Trials.gov.